血清生物标志物组合可预测肝硬化患者肝癌风险
一项纵向III期研究纳入2266例成人肝硬化患者,随访至发生肝癌(n=126),通过定制FirePlex免疫测定检测39种基线血清标志物,识别出九种生物标志物组合(P9),其C-index为0.67,加入临床模型或aMAP评分可提高1年和2年AUROC,且不依赖AFP-L3或DCP。
要点
- 九种血清生物标志物组合P9与肝硬化患者肝癌发生独立相关。
- P9加入含10因素(包括AFP)的临床模型,1年和2年AUROC分别提高4.8%和2.7%。
- P9加入aMAP评分,1年和2年AUROC分别提高14.2%和7.6%。
核心结论
- 九种血清生物标志物组合P9与肝硬化患者发生肝癌独立相关,并能提升含临床因素的风险分层模型的预测能力。
研究设计与样本
- 纵向III期研究,使用前瞻性队列2266例成人肝硬化患者的血清和数据,随访至发生肝癌(n=126)。
- 定制FirePlex免疫测定检测39种基线血清标志物,采用bootstrapping评估预测性能(C-index和时间依赖AUROC)。
主要发现
- 识别出九种生物标志物组合P9,C-index为0.67(95% CI 0.66至0.67)。
- P9加入含10因素(包括AFP)的临床模型,1年和2年AUROC分别提高4.8%和2.7%。
- P9加入aMAP评分,1年和2年AUROC分别提高14.2%和7.6%。
- 加入AFP L-3或DCP未改变P9模型的预测能力。
关键数值与推荐
- P9包含:胰岛素样生长因子-1、白细胞介素-10、转化生长因子β1、Adipsin、胎球蛋白-A、白细胞介素-1β、巨噬细胞刺激蛋白α链、血清淀粉样蛋白A和TNF-α。
临床怎么用
- 在肝硬化患者中,可考虑检测P9生物标志物组合以辅助肝癌风险分层,补充现有临床模型或aMAP评分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammatory and metabolic biomarkers have been associated with hepatocellular cancer (HCC) risk in phases I and II biomarker studies. We developed and internally validated a robust metabolic biomarker panel predictive of HCC in a longitudinal phase III study. METHODS: We used data and banked serum from a prospective cohort of 2266 adult patients with cirrhosis who were followed until the development of HCC (n=126). We custom designed a FirePlex immunoassay to measure baseline serum levels of 39 biomarkers and established a set of biomarkers with the highest discriminatory ability for HCC. We performed bootstrapping to evaluate the predictive performance using C-index and time-dependent area under the receiver operating characteristic curve (AUROC). We quantified the incremental predictive value of the biomarker panel when added to previously validated clinical models. RESULTS: We identified a nine-biomarker panel (P9) with a C-index of 0.67 (95% CI 0.66 to 0.67), including insulin growth factor-1, interleukin-10, transforming growth factor β1, adipsin, fetuin-A, interleukin-1 β, macrophage stimulating protein α chain, serum amyloid A and TNF-α. Adding P9 to our clinical model with 10 factors including AFP improved AUROC at 1 and 2 years by 4.8% and 2.7%, respectively. Adding P9 to aMAP score improved AUROC at 1 and 2 years by 14.2% and 7.6%, respectively. Adding AFP L-3 or DCP did not change the predictive ability of the P9 model. CONCLUSIONS: We identified a panel of nine serum biomarkers that is independently associated with developing HCC in cirrhosis and that improved the predictive ability of risk stratification models containing clinical factors.
引用
- El-Serag H, Kanwal F, Ning J, et al. Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis. Gut. 2024. PMID: 38365278. doi:10.1136/gutjnl-2024-332034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。